Another Experimental Use Authorization Merck’s Oral Antiviral ‘Molnupiravir’

Want Instant Blog Updates?

Get an email whenever we publish a new article!
PLEASE NOTE:
This subscribe option does not work in some browsers with ad blockers. To ensure your sign up request goes through, use the Google Chrome browser when confirming your subscription from your inbox.

October 2, 2021

Merck has announced they will be seeking EUA in the U.S. as soon as possible as well as making application to regulatory agencies across the planet for the first oral Antiviral medication for COVID-19. 

Access The Epoch Times online article from October 1, 2021 here which prompted claims that Merck’s antiviral pill for COVID-19 is effective.

Access the Epoch Times pdf article stored in our Library here

 

Access the Journal of Geopolitics and International Relations online article here for everything you need to know about Merck’s Covid pill.

“A whistleblower complaint has surfaced regarding Molnupiravir suggesting it is an antiviral retread from influenza research, has mutagenic properties and may change your DNA”. 

Access the pdf Library article “All You Need To Know About Merck’s Covid Pill Molnupiravir” here
ACCESS The Merck News Press Release on 10/1/21 on Interim Analysis of Phase 3 Study Here

 

We've got a lot to talk about

Read More